SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has appointed Matthew W. Foehr to the newly created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Foehr will primarily be responsible for managing the operations and strategic expansion of CyDex Pharmaceuticals, a specialty pharmaceutical company acquired by Ligand in January 2011 and overseeing Ligand’s research and development programs.
